This Article  • Full text  • PDF  • eSupplement  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Treatment Adherence  • Drug Therapy  • Adherence  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Matthew D. Solomon, MD, PhD; Dana P. Goldman, PhD; Geoffrey F. Joyce, PhD; José J. Escarce, MD, PhD

Arch Intern Med. 2009;169(8):740-748.

Background  Increased cost sharing reduces utilization of prescription drugs, but little evidence demonstrates how this reduction occurs or the factors associated with price sensitivity.

Methods  We conducted a retrospective cohort study of older adults with employer-provided drug coverage from 1997 to 2002 from 31 different health plans. We measured the time until initiation of medical therapy for 17 183 patients with newly diagnosed hypertension, diabetes, or hypercholesterolemia.

Results  For all study conditions, higher copayments were associated with delayed initiation of therapy. In survival models, doubling copayments resulted in large reductions in the predicted proportion of patients initiating pharmacotherapy at 1 and 5 years after diagnosis: for hypertension, 54.8% vs 39.9% at 1 year and 81.6% vs 66.2% at 5 years (P < .001); for hypercholesterolemia, 40.2% vs 31.1% at 1 year and 64.3% vs 53.8% at 5 years (P < .002); and for diabetes, 45.8% vs 40.0% at 1 year and 69.3% vs 62.9% at 5 years (P < .04). However, patients' rate of initiation and sensitivity to copayments strongly depended on their prior experience with prescription drugs. Those without prior drug use (26.1%, 10.4%, and 12.9%) initiated later (833, >1170, and >1402 days later in median time until initiation) and were far more price sensitive (increase of 34.5%, 20.1%, and 27.2% remaining untreated after 5 years when copayments doubled) than those with a history of drug use among patients with newly diagnosed hypertension, hypercholesterolemia, and diabetes, respectively. These results were robust to a wide range of sensitivity analyses.

Conclusions  High cost sharing delays the initiation of drug therapy for patients newly diagnosed with chronic disease. This effect is greater among patients who lack experience with prescription drugs. Policy makers and physicians should consider the effects of benefits design on patient behavior to encourage the adoption of necessary care.

Author Affiliations: Department of Medicine, Stanford University School of Medicine, Stanford, California (Dr Solomon); RAND Corporation, Santa Monica, California (Drs Solomon, Goldman, Joyce, and Escarce); and Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles (Dr Escarce).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The year in epidemiology, health services research, and outcomes research.
Hlatky and Heidenreich
J Am Coll Cardiol 2009;54:2343-2351.
FULL TEXT  

A model for NICE in the US
Ferner and McDowell
BMJ 2009;338:b2221-b2221.
FULL TEXT  

Effect of Out-of-Pocket Drug Expenses on Initiation of Drug Therapy
JWatch General 2009;2009:10-10.
FULL TEXT  

The Change We Need in Health Care
Goff and Greenland
Arch Intern Med 2009;169:737-739.
FULL TEXT